Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) reported on Friday that its lead drug for inflammatory bowel disease (IBD) is Emoxypine (NP-178),a small molecule delivered orally. It is one of the top-five selling drugs on the essential medicines list in Russia for the treatment of several neurological conditions.
For more on this, click here.
Earlier this week, AGN stated that its lead compoundto treat non-alcoholic steatohepatitis and chronic kidney disease, Bemethyl (NP-135) and Bromantane (NP-160), outperformed known anti-fibrotic agents. Both drugs are types of “actoprotectors”, developed as athletic performance enhancing drugs by the Soviet Union.
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.